Special access opens for progressive MS patients out of options
NCT ID NCT04540861
Summary
This program provided special access to the drug siponimod for adults with a specific, active form of progressive multiple sclerosis (SPMS) who had no other satisfactory treatment available. It was not a standard clinical trial but a managed access plan, allowing doctors to request the drug for eligible patients. The goal was to help control the disease in patients who had run out of other approved options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.